8-K: Aprea Therapeutics Reports Positive WEE1 Inhibitor Data

Aprea Therapeutics announced fourth quarter and full year 2025 financial results, highlighted by early clinical proof-of-concept for its WEE1 inhibitor APR-1051 and a strengthened cash position.

Summary

• Reported financial results for the fourth quarter and full year ended December 31, 2025.
• WEE1 inhibitor APR-1051 showed early clinical proof-of-concept in the ACESOT-1051 trial with two unconfirmed partial responses at first scan in endometrial cancer patients with PPP2R1A mutation.
• APR-1051 was safe and well-tolerated, with top two adverse events reported as Grade 1 or 2 nausea and fatigue.
• Dose escalation for APR-1051 is ongoing, with patients currently being treated at Dose Level 8 (220 mg once daily).
• ATR inhibitor ATRN-119's recommended Phase 2 dose (RP2D) was determined at 1,100 mg for once daily dosing, but monotherapy enrollment has been strategically paused to explore combination approaches.
• Completed two private placements in December 2025 and January 2026, raising gross proceeds of approximately $3.1 million and $5.6 million, respectively.
• Appointed Eugene (Gene) Kennedy, MD, as Chief Medical Advisor in February 2026.
• Cash and cash equivalents were $14.6 million as of December 31, 2025, with a projected cash runway into the first quarter of 2027, including proceeds from the January 2026 private placement.
• Operating loss for Q4 2025 was $2.6 million, compared to $3.2 million in Q4 2024.
• Operating loss for the full year 2025 was $13.2 million, compared to $14.3 million for the full year 2024.
• Net loss for Q4 2025 was $2.5 million ($0.32 per basic share), compared to $2.9 million ($0.49 per basic share) in Q4 2024.
• Net loss for the full year 2025 was $12.6 million ($1.93 per basic share), compared to $13.0 million ($2.35 per basic share) for the full year 2024.
• Research and Development (R&D) expenses decreased in both Q4 and full year 2025 primarily due to lower clinical trial expenses and personnel costs.
• General and Administrative (G&A) expenses increased in Q4 2025 due to incentive compensation but remained stable for the full year 2025 compared to 2024.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, driven by promising early clinical data for APR-1051 and improved financial runway, despite ongoing losses and a strategic pause for ATRN-119 monotherapy.

Positives

• Early clinical proof-of-concept for WEE1 inhibitor APR-1051 with two unconfirmed partial responses in endometrial cancer patients with PPP2R1A mutation, demonstrating anti-tumor activity.
• APR-1051 has been safe and well tolerated, with top adverse events reported as Grade 1 or 2 nausea and fatigue, suggesting a potentially favorable therapeutic window.
• Successful private placements in December 2025 and January 2026 raised approximately $8.7 million in gross proceeds, strengthening the company's financial flexibility.
• Cash and cash equivalents, combined with the recent capital raise, are projected to fund operations into the first quarter of 2027, extending the financial runway.
• Operating loss and net loss decreased in both the fourth quarter and full year 2025 compared to the respective periods in 2024.
• Appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor strengthens the clinical development team with over 20 years of oncology experience.
• APR-1051 shows single agent activity in cancer cells with mutated PPP2R1A, FBXW7, and HPV+ head and neck tumor cells, indicating broad potential.

Negatives

• ATR inhibitor ATRN-119 monotherapy enrollment was strategically paused, indicating a shift in development strategy for this asset and potential delays in its standalone progression.
• Grant revenues significantly decreased from $1.5 million for the year ended December 31, 2024, to $0.3 million for the year ended December 31, 2025.
• The company continues to report net losses, with a net loss of $2.5 million in Q4 2025 and $12.6 million for the full year 2025.
• Cash and cash equivalents decreased from $22.8 million as of December 31, 2024, to $14.6 million as of December 31, 2025, prior to the January 2026 capital raise.

Risks

• Risks related to the success, timing, and cost of ongoing clinical trials and anticipated clinical trials for current product candidates.
• Uncertainty regarding the timing of initiation, pace of enrollment, and completion of clinical trials.
• The ability to fully fund disclosed clinical trials, which assumes no material changes to currently projected expenses.
• Futility analyses, presentations at conferences, and data reported in abstracts, and receipt of interim or preliminary results (including preclinical results or data), are not necessarily indicative of the final results of ongoing clinical trials.
• The company's understanding of product candidates' mechanisms of action and interpretation of preclinical and early clinical results, and its ability to predict clinical outcomes based on such results.
• The ability to continue as a going concern.
• Actual results and developments could be materially different from forward-looking statements due to inaccurate assumptions or by known or unknown risks and uncertainties.

Future Outlook

The company expects a further update from the ACESOT-1051 trial in the second quarter of 2026 and aims to complete dose escalation for APR-1051 in Q3 2026. They are exploring potential collaborations for ATRN-119 combinations in the second half of 2026. Cash and cash equivalents, including proceeds from recent private placements, are projected to fund operations into the first quarter of 2027.

Management Comments

• "We enter 2026 with strong momentum following a year of meaningful execution across our portfolio." Oren Gilad, Ph.D., President and Chief Executive Officer.
• "We are particularly encouraged by the most recent data from the ongoing ACESOT trial evaluating APR-1051, including two patients achieving unconfirmed partial responses at first scan." Oren Gilad, Ph.D., President and Chief Executive Officer.
• "These results provide early proof of clinical concept for APR-1051 and strengthen our conviction in the product's ability to deliver a favorable therapeutic window, supporting its potential to be a differentiated WEE1 kinase inhibitor for patients with genomically defined solid tumors who have limited treatment options." Oren Gilad, Ph.D., President and Chief Executive Officer.
• "We strengthened our balance sheet with successful private placements in late 2025 and early 2026, enhancing our financial flexibility and positioning the Company to execute on key development milestones." Oren Gilad, Ph.D., President and Chief Executive Officer.
• "We believe the recent progress underscores the opportunity within our DDR portfolio and reinforces our goal of developing targeted cancer therapies that have the potential to improve outcome and quality of life for patients, while also creating value for our shareholders." Oren Gilad, Ph.D., President and Chief Executive Officer.

Industry Context

StockSavvy.ai notes that Aprea Therapeutics is positioning itself within the competitive precision oncology landscape by focusing on DNA Damage Response (DDR) pathways. The early clinical proof-of-concept for APR-1051, a WEE1 inhibitor, in biomarker-defined cancers aligns with the industry's shift towards targeted therapies. The strategic pause in ATRN-119 monotherapy development to explore combination approaches reflects a common industry practice to optimize therapeutic benefit and address the complexities of cancer treatment, where single agents often have limited efficacy in advanced settings.

Comparison to Industry Standards

• APR-1051 aims to expand the therapeutic index compared to earlier WEE1 inhibitors like Adavosertib (AstraZeneca), which was terminated due to hematologic and GI toxicity, and Azenosertib (Zentalis), which requires ongoing dosing and schedule optimization due to tolerability issues.
• Debio 0123 (Debiopharm) showed QT prolongation liability at high doses and limited single-agent activity, with no clinical responses at doses up to MTD, indicating cardiac safety restrictions on exposure.
• APR-1051's early signals of tumor reduction without class-limiting toxicity to date suggest a potentially widened therapeutic window compared to these competitors.
• Preclinical data indicates APR-1051 is a potent WEE1 inhibitor that does not substantially inhibit PLK1, PLK2, or PLK3, unlike ZN-c3 (Azenosertib), which shows significant off-target inhibition of these PLK enzymes. This selectivity is crucial as PLK1 inhibition has been associated with reduced cytotoxic effects of WEE1 inhibitors and potential sepsis-induced intestinal barrier dysfunction.

Management Changes

Stakeholder Impact

• Shareholders: Potential positive impact from promising early clinical data for APR-1051 and extended cash runway, but continued losses and strategic shift for ATRN-119 introduce uncertainty.
• Patients: Potential benefit from the development of targeted therapies for biomarker-defined cancers, especially with early signs of efficacy for APR-1051 in difficult-to-treat conditions.
• Employees: The appointment of a new Chief Medical Advisor indicates continued investment in leadership, but the strategic pause in ATRN-119 monotherapy could imply resource reallocation.
• Creditors: Strengthened cash position from private placements reduces immediate liquidity concerns.

Next Steps

• Enroll additional patients in the ACESOT-1051 trial to enrich for endometrial, colorectal, and HPV+ tumors.
• Further update from ACESOT-1051 trial expected in Q2 2026.
• Complete dose escalation for APR-1051 in Q3 2026.
• Explore ATRN-119 in potential combination approaches, including discussions with academic institutions for combination with radiation in HPV+ head and neck cancer.
• Explore additional investigator-led studies evaluating ATRN-119 with immuno-oncology therapies and antibody-drug conjugates.
• Evaluate optimal strategic partnerships.

Key Dates

Recommendation

The early clinical proof-of-concept for APR-1051 is a significant positive, demonstrating potential in a challenging oncology space and differentiating it from competitors. The extended cash runway also provides stability. However, the company remains unprofitable, and the strategic pause in ATRN-119 monotherapy introduces uncertainty regarding that asset's future. While the clinical data is encouraging, it is still early-stage (Phase 1, unconfirmed responses). A "hold" recommendation is appropriate as investors should await further, more mature clinical data and clearer development pathways for both pipeline assets before making a stronger commitment.

Keywords

Aprea Therapeutics, APRE, WEE1 inhibitor, APR-1051, ATR inhibitor, ATRN-119, oncology, precision medicine, cancer, clinical trial, financial results, Q4 2025, full year 2025, endometrial cancer, PPP2R1A mutation, corporate update, capital raise, drug development, biotechnology, Nasdaq